Metraipolis › archive › dc_5ece5e71d305
Enhancement of gemcitabine toxicity and specificity through PI3K/Akt/Nrf2 pathway inhibition in pancreatic cancer — Europe PMC PMID:41777246
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41777246
- DOI
- 10.3389/fphar.2026.1724989
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-05T17:53:33.247Z
- SHA-256 of the archived text
6324a2854117833759c4c2be73e0a1f275858183905cd35c1385b5800717d59b- Stable URL of this page
https://metraipolis.com/documento/dc_5ece5e71d305
How to cite
Enhancement of gemcitabine toxicity and specificity through PI3K/Akt/Nrf2 pathway inhibition in pancreatic cancer — Europe PMC PMID:41777246 — Europe PMC (en), https://europepmc.org/article/MED/41777246 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5ece5e71d305 (Metraipolis archive dc_5ece5e71d305, sha256 6324a2854117833759c4c2be73e0a1f275858183905cd35c1385b5800717d59b)
BibTeX
@misc{dc5ece5e71d305,
title = {Enhancement of gemcitabine toxicity and specificity through PI3K/Akt/Nrf2 pathway inhibition in pancreatic cancer — Europe PMC PMID:41777246},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41777246},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5ece5e71d305; sha256 6324a2854117833759c4c2be73e0a1f275858183905cd35c1385b5800717d59b},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41777246. Agents can read the archived copy with the MCP tool read_document.